Ergothioneine supplementation in people with metabolic syndrome (ErgMS): protocol for a randomised, double-blind, placebo-controlled pilot study

Xiaoying Tian; Giorgia Cioccoloni; Joanna H Sier; Khalid M Naseem; James L Thorne; J Bernadette Moore

doi:10.1186/s40814-021-00929-6

Ergothioneine supplementation in people with metabolic syndrome (ErgMS): protocol for a randomised, double-blind, placebo-controlled pilot study

Pilot Feasibility Stud. 2021 Oct 29;7(1):193. doi: 10.1186/s40814-021-00929-6.

Authors

Xiaoying Tian¹, Giorgia Cioccoloni¹, Joanna H Sier¹, Khalid M Naseem², James L Thorne¹, J Bernadette Moore³

Affiliations

¹ School of Food Science & Nutrition, University of Leeds, Leeds, LS2 9JT, UK.
² Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, LS2 9JT, UK.
³ School of Food Science & Nutrition, University of Leeds, Leeds, LS2 9JT, UK. J.B.Moore@leeds.ac.uk.

Abstract

Background: Ergothioneine is a naturally occurring metabolite of histidine found in many foods and in high amounts in mushrooms. In vivo, ergothioneine acts as an antioxidant and is widely distributed in most mammalian tissues. While ergothioneine is sold as a dietary supplement for its antioxidant and anti-inflammatory properties, to date there are no published intervention trials examining its health benefits in humans. The aim of this work was to develop a study protocol for a pilot interventional trial that will establish the primary and secondary outcomes, and the power required, for a definitive randomised controlled trial to test the hypothesis that ergothioneine supplementation is beneficial for people with metabolic syndrome.

Methods: We have designed the ErgMS study as a single-centre, randomised, double-blind, placebo-controlled, 3-arm parallel, pilot intervention trial, which aims to supplement participants with either placebo, 5 or 30 mg/day ergothioneine for 12 weeks. Measurements of metabolic syndrome risk factors, serum markers of oxidative stress (lipid peroxidation), inflammation, blood platelet function and liver function will take place at baseline, and after 6 weeks and 12 weeks of supplementation. In addition, we will examine if there are any changes in the serum metabolome in response to ergothioneine supplementation. Linear regression and two-way ANOVA will be utilised to analyse the association between ergothioneine and measured variables.

Discussion: The ErgMS study will be the first study to address the question does ergothioneine supplementation have health benefits for people with metabolic syndrome. Study results will provide preliminary data as to which dose may improve inflammatory markers in adults with metabolic syndrome and will inform dose and primary outcome selection for a definitive randomised controlled trial.

Trial registration: ISRCTN, ISRCTN25890011 Registered February 10^th, 2021.

Keywords: ALT; Ergothioneine; Inflammation; Metabolic syndrome; Metabolome; Oxidative stress; Supplementation.